Olaparib 100mg, 150mg Tablets — PARP Inhibitor for BRCA-Mutated Cancers
Bracanat® (Olaparib) — PARP Inhibitor for BRCA-Mutated Ovarian, Breast, Pancreatic and Prostate Cancers
Targeted Therapy for BRCA1/2 Mutation-Positive Cancers
Bracanat® (Olaparib) is a poly ADP-ribose polymerase (PARP) inhibitor used to treat cancers with BRCA1 or BRCA2 mutations. It is approved for ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer with specific BRCA or HRR mutations. Bracanat works by blocking PARP enzymes that cancer cells depend on to repair their DNA, causing cancer cell death through a mechanism known as synthetic lethality.
A.K. Pharma is a trusted medicine distributor in Delhi supplying genuine Bracanat (Olaparib) to hospitals, oncology centres, clinics, and pharmacies across India. Olaparib is also available as Lynpraza — another brand of Olaparib available at A.K. Pharma. Both are manufactured by AstraZeneca, a global leader in oncology.
What is Bracanat (Olaparib)?
Bracanat contains Olaparib, a first-in-class oral PARP inhibitor. PARP (Poly ADP-Ribose Polymerase) is an enzyme that helps cells repair single-strand DNA breaks. Cancer cells with BRCA1 or BRCA2 mutations already have impaired double-strand DNA repair. By inhibiting PARP, Bracanat creates overwhelming DNA damage in BRCA-mutated cancer cells that they cannot repair, leading to cell death.
This concept — where two individually sublethal defects (BRCA mutation + PARP inhibition) combine to cause cell death — is known as synthetic lethality. This mechanism makes Bracanat highly selective for BRCA-mutated cancer cells while sparing normal cells.
Full prescribing information is available at the FDA label for Olaparib.
Clinical Studies and Evidence
SOLO-1 Trial (Olaparib Maintenance in BRCA-Mutated Ovarian Cancer) Published in the New England Journal of Medicine (2018), the SOLO-1 trial demonstrated that Olaparib maintenance therapy significantly improved progression-free survival in patients with newly diagnosed advanced BRCA-mutated ovarian cancer who responded to platinum-based chemotherapy, with a 70% reduction in the risk of progression or death at 3 years compared to placebo.
SOLO-2 Trial (Olaparib Maintenance in Relapsed BRCA-Mutated Ovarian Cancer) Published in the Lancet Oncology (2017), the SOLO-2 trial showed Olaparib maintenance significantly improved progression-free survival in relapsed BRCA-mutated ovarian cancer, with a median PFS of 19.1 months vs 5.5 months for placebo.
OlympiAD Trial (Olaparib for BRCA-Mutated Breast Cancer) Published in the New England Journal of Medicine (2017), the OlympiAD trial demonstrated Olaparib significantly improved PFS compared to standard chemotherapy in patients with BRCA1/2-mutated HER2-negative metastatic breast cancer.
POLO Trial (Olaparib for BRCA-Mutated Pancreatic Cancer) Published in the New England Journal of Medicine (2019), the POLO trial showed Olaparib maintenance significantly improved PFS in patients with germline BRCA-mutated metastatic pancreatic cancer who had not progressed on first-line platinum-based chemotherapy.
PROfound Trial (Olaparib for BRCA-Mutated Prostate Cancer) Published in the New England Journal of Medicine (2020), the PROfound trial demonstrated Olaparib significantly improved radiographic PFS in patients with HRR gene-mutated metastatic castration-resistant prostate cancer who had progressed on enzalutamide or abiraterone.
Available Strengths
Bracanat is available in the following strengths:
The recommended dose is 300mg (two 150mg tablets) twice daily — a total daily dose of 600mg. Treatment continues until disease progression or unacceptable toxicity.
Indications — What Bracanat is Used For
Ovarian Cancer
Breast Cancer
Pancreatic Cancer
Prostate Cancer
For detailed indication information refer to NCI Olaparib Drug Information.
Key Benefits of Bracanat
Broad Oncology Indications Bracanat is approved across four cancer types — ovarian, breast, pancreatic, and prostate — making it one of the most versatile targeted cancer therapies available.
Oral Administration Bracanat is taken as tablets twice daily, eliminating the need for intravenous infusions and allowing patients to continue treatment at home.
Proven PFS Benefit Across Multiple Cancers Multiple Phase 3 trials have demonstrated significant and consistent progression-free survival benefits across all approved indications.
Synthetic Lethality — Precision Oncology Bracanat’s mechanism exploits a specific vulnerability in BRCA-mutated cancer cells, making it a true precision medicine that targets cancer cells while having relatively low impact on normal cells.
Maintenance Therapy Option Bracanat is approved as maintenance therapy following platinum-based chemotherapy in ovarian cancer, helping to prolong the response achieved with initial treatment.
How Bracanat Works
Normal cells have multiple DNA repair pathways. BRCA1 and BRCA2 are tumour suppressor genes that play a critical role in homologous recombination repair (HRR) of double-strand DNA breaks. Cancer cells with BRCA mutations have defective HRR and rely heavily on PARP-mediated repair of single-strand DNA breaks to survive.
Bracanat works by:
This mechanism is explained in detail at Cancer Research UK — PARP Inhibitors.
BRCA Testing Before Treatment
BRCA mutation testing is required before initiating Bracanat therapy. Testing can be performed on:
Patients with germline BRCA1/2 mutations are eligible for Bracanat across all approved indications. Patients with somatic BRCA mutations may also be eligible depending on the cancer type and specific indication. Testing should be performed using an FDA-approved or validated companion diagnostic test.
Dosage and Administration
Full dosing guidelines available at Drugs.com Olaparib Dosage.
Who Should Use Bracanat
Bracanat is prescribed for:
Bracanat is prescribed by oncologists, gynaecological oncologists, breast oncologists, and urological oncologists. A.K. Pharma supplies Bracanat to oncology centres, hospitals, and pharmacies across Delhi and India.
Possible Side Effects
Common side effects include nausea, fatigue, anaemia, vomiting, diarrhoea, decreased appetite, headache, neutropenia, thrombocytopenia, and abdominal pain.
Serious side effects include:
Full side effect information available at FDA Olaparib Safety Information.
Precautions
Storage and Handling
As a responsible medicine distributor in Delhi, A.K. Pharma stores all medicines including Bracanat under manufacturer-recommended conditions ensuring product integrity and efficacy for every supply.
Manufacturer Information
Bracanat (Olaparib) is manufactured by AstraZeneca in partnership with Merck (MSD). Olaparib received initial FDA approval in December 2014 as the first PARP inhibitor approved for cancer treatment. A.K. Pharma supplies only genuine Bracanat sourced from authorized distributors.
Related Cancer Medicines Available at A.K. Pharma
Frequently Asked Questions
Q. What is Bracanat used for? Bracanat (Olaparib) is used to treat BRCA-mutated ovarian, breast, pancreatic, and prostate cancers. It is a PARP inhibitor that works through synthetic lethality in BRCA-mutated cancer cells. More information available at Cancer.gov.
Q. What is the generic name of Bracanat? The generic name of Bracanat is Olaparib. It belongs to the PARP inhibitor class of targeted cancer therapies. Olaparib is also available as Lynpraza.
Q. Is BRCA testing required before starting Bracanat? Yes. BRCA mutation testing is required before initiating Bracanat therapy. Testing can be performed on tumour tissue or blood/saliva depending on the specific indication.
Q. Is Bracanat available in India? Bracanat can be supplied to hospitals, oncology centres, and pharmacies across India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi — for availability and pricing.
Q. What is the difference between Bracanat and Lynpraza? Both Bracanat and Lynpraza contain the same active ingredient Olaparib and have the same indications and efficacy. They are different brand names of the same medicine. A.K. Pharma supplies both brands — contact us for current availability and pricing.
Q. What is the price of Bracanat in India? Bracanat price in India varies by strength and pack size. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.
Q. How to order Bracanat from A.K. Pharma? You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.
Q. Does A.K. Pharma supply Bracanat in bulk? Yes. A.K. Pharma supplies Bracanat in bulk to oncology centres, hospitals, and pharmacies across Delhi and India. Contact us for bulk pricing and availability.
Why Order Bracanat from A.K. Pharma?
Contact A.K. Pharma for Bracanat Supply 📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052 📞 011 4172 6999 📱 WhatsApp: +91 9810034827 🌐 akpharma.in
